Mutual of America Capital Management’s Emergent Biosolutions EBS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-126,596
| Closed | -$1.31M | – | 1476 |
|
|
2023
Q1 | $1.31M | Buy |
126,596
+57,130
| +82% | +$691K | 0.02% | 1004 |
|
|
2022
Q4 | $820K | Sell |
69,466
-28,613
| -29% | -$443K | 0.01% | 1051 |
|
|
2022
Q3 | $2.06M | Buy |
98,079
+11,759
| +14% | +$327K | 0.03% | 840 |
|
|
2022
Q2 | $2.68M | Buy |
86,320
+21
| +0% | +$717 | 0.03% | 744 |
|
|
2022
Q1 | $3.54M | Sell |
86,299
-3,096
| -3% | -$137K | 0.04% | 715 |
|
|
2021
Q4 | $3.89M | Buy |
89,395
+14,174
| +19% | +$641K | 0.04% | 695 |
|
|
2021
Q3 | $3.77M | Buy |
75,221
+1,976
| +3% | +$120K | 0.04% | 682 |
|
|
2021
Q2 | $4.61M | Sell |
73,245
-25,500
| -26% | -$1.64M | 0.05% | 576 |
|
|
2021
Q1 | $9.17M | Sell |
98,745
-4,622
| -4% | -$473K | 0.1% | 232 |
|
|
2020
Q4 | $9.26M | Sell |
103,367
-1,258
| -1% | -$115K | 0.11% | 200 |
|
|
2020
Q3 | $10.8M | Sell |
104,625
-27,675
| -21% | -$2.98M | 0.14% | 117 |
|
|
2020
Q2 | $10.5M | Sell |
132,300
-9,793
| -7% | -$730K | 0.15% | 111 |
|
|
2020
Q1 | $8.22M | Buy |
142,093
+34,744
| +32% | +$2M | 0.14% | 130 |
|
|
2019
Q4 | $5.79M | Sell |
107,349
-80,501
| -43% | -$4.37M | 0.07% | 363 |
|
|
2019
Q3 | $9.82M | Buy |
187,850
+6,905
| +4% | +$322K | 0.14% | 145 |
|
|
2019
Q2 | $8.74M | Buy |
180,945
+34,176
| +23% | +$1.64M | 0.12% | 161 |
|
|
2019
Q1 | $7.42M | Buy |
146,769
+1,793
| +1% | +$106K | 0.11% | 214 |
|
|
2018
Q4 | $8.59M | Sell |
144,976
-811
| -0.6% | -$52.3K | 0.14% | 134 |
|
|
2018
Q3 | $9.6M | Buy |
145,787
+15,550
| +12% | +$907K | 0.14% | 141 |
|
|
2018
Q2 | $6.58M | Sell |
130,237
-164
| -0.1% | -$8.54K | 0.1% | 255 |
|
|
2018
Q1 | $6.87M | Sell |
130,401
-214
| -0.2% | -$10.7K | 0.11% | 231 |
|
|
2017
Q4 | $6.07M | Buy |
130,615
+3,325
| +3% | +$140K | 0.09% | 300 |
|
|
2017
Q3 | $5.15M | Buy |
127,290
+1,287
| +1% | +$46.6K | 0.08% | 334 |
|
|
2017
Q2 | $4.27M | Sell |
126,003
-4,055
| -3% | -$125K | 0.07% | 432 |
|
|
2017
Q1 | $3.78M | Sell |
130,058
-55,603
| -30% | -$1.69M | 0.07% | 478 |
|
|
2016
Q4 | $6.1M | Sell |
185,661
-19,495
| -10% | -$584K | 0.11% | 211 |
|
|
2016
Q3 | $6.47M | Buy |
205,156
+215
| +0.1% | +$6.25K | 0.13% | 168 |
|
|
2016
Q2 | $5.76M | Buy |
204,941
+1,152
| +0.6% | +$45.2K | 0.12% | 191 |
|
|
2016
Q1 | $7.41M | Sell |
203,789
-1,130
| -0.6% | -$39.9K | 0.16% | 111 |
|
|
2015
Q4 | $8.2M | Buy |
204,919
+4,539
| +2% | +$158K | 0.18% | 92 |
|
|
2015
Q3 | $5.71M | Sell |
200,380
-125
| -0.1% | -$4.12K | 0.14% | 146 |
|
|
2015
Q2 | $6.61M | Buy |
200,505
+40,720
| +25% | +$1.26M | 0.14% | 134 |
|
|
2015
Q1 | $4.59M | Sell |
159,785
-4,599
| -3% | -$132K | 0.1% | 262 |
|
|
2014
Q4 | $4.48M | Buy |
164,384
+2,608
| +2% | +$62.2K | 0.1% | 261 |
|
|
2014
Q3 | $3.45M | Hold |
161,776
| – | – | 0.08% | 349 |
|
|
2014
Q2 | $3.63M | Buy |
161,776
+28,286
| +21% | +$659K | 0.09% | 343 |
|
|
2014
Q1 | $3.37M | Buy |
133,490
+5,700
| +4% | +$144K | 0.08% | 379 |
|
|
2013
Q4 | $2.94M | Buy |
127,790
+38,667
| +43% | +$806K | 0.07% | 446 |
|
|
2013
Q3 | $1.7M | Buy |
89,123
+2,248
| +3% | +$40.1K | 0.05% | 677 |
|
|
2013
Q2 | $1.25M | Buy |
+86,875
| New | +$1.26M | 0.04% | 796 |
|
Other funds holding EBS
Mutual of America Capital Management's EBS Position: Q2 2023 in Review
Mutual of America Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2023, closing a stake of 126,596 shares — an estimated $1.31M sold.
Mutual of America Capital Management first reported a position in EBS in Q2 2013 and held it in 40 quarters. The position peaked at $10.8M in Q3 2020. 183 funds tracked by Wall St. Rank hold EBS as of Q2 2023.
- Mutual of America Capital Management reported no remaining Emergent Biosolutions position as of Q2 2023 after selling out during the quarter.
- Mutual of America Capital Management sold 126,596 Emergent Biosolutions shares in Q2 2023, an estimated $1.31M.
- Mutual of America Capital Management first reported a position in Emergent Biosolutions in Q2 2013 and held it in 40 quarters.
- Mutual of America Capital Management's Emergent Biosolutions position peaked at $10.8M in Q3 2020.
- 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2023.
Based on Mutual of America Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.